BB BIOTECH N Logo
CH0038389992
A0NFN3
BBZA.DE

BB BIOTECH N

Caricamento quotazioni...

Previsioni

Non sono disponibili dati degli analisti per questa azienda.

Discussioni nella community

  • Split BB Biotech 2016

    Rainer Rainer I in Schnack

    0 3

  • BB Biotech makes twelve new investments after sale of Crinetics and Nuvalent

    BB Biotech realised about CHF 280 million in Q3 by selling Crinetics Pharmaceuticals and Nuvalent and immediately deployed the proceeds into twelve new positions. Larger purchases included Biogen, Incyte and Axsome Therapeutics; Alnylam was re-added to the portfolio after a price drop. Other new investments cover advanced development programmes such as Kodiak Sciences, Summit Therapeutics, LB Pharmaceuticals and Bicara, as well as smaller starter positions in Alto Neuroscience, Yarrow Bioscience and Eupraxia. Private holdings remain limited, while BB Biotech sees room to expand positions if clinical evidence is positive; the stock has picked up momentum again after a period of consolidation. » Altro su deraktionaer.de


  • BB Biotech expands portfolio and adds twelve new positions

    BB Biotech expanded its portfolio by twelve new holdings in the third quarter and reinvested around CHF 280 million from takeovers. The new additions range from established biotech companies with product revenues to clinical-stage developers with upcoming milestones. The purchases aim to find stocks whose market valuations do not yet fully reflect their scientific, clinical and commercial potential. » Altro su finanzen.net


  • BB Biotech posts profit again in third quarter and sees targeted investment opportunities

    BB Biotech recorded a profit of CHF 175 million in the third quarter, marking the second consecutive profitable quarter. The net asset value rose 5.6% in CHF during the quarter, and the company reports clinical and regulatory progress at portfolio companies. After the September correction, BB Biotech sees targeted buying opportunities in stocks whose prices have fallen despite unchanged clinical prospects; further milestones are expected in the fourth quarter. » Altro su finanzen.net


  • BB Biotech: AI could trigger a new innovation-driven growth cycle in the biotech sector

    BB Biotech and Medpace are among the stocks traders are currently backing, as AI-supported models could accelerate drug development and spark broader innovation across the sector. After years dominated by GLP-1 and individual blockbusters, multiple biotech companies could now benefit from more efficient drug discovery and new discoveries. The article names three biotech stocks at 52-week highs that traders should keep an eye on. » Altro su finanzen.net


  • BB Biotech: comeback gains momentum as analysts recommend selling numerous stocks

    Last trading week, numerous analysts advised exiting various stocks and issued multiple sell recommendations. At the same time, BB Biotech reported a stronger comeback with solid quarterly results and a portfolio that outperforms the industry index, while the stock still lags its intrinsic value. » Altro su finanzen.net

Nel 2026, BB BIOTECH N ha già distribuito 2,46 € di dividendi. L'ultimo pagamento è avvenuto a marzo.

Dati finanziari dell'azienda

Nell'ultimo trimestre, BB BIOTECH N ha registrato ricavi pari a 99,79 Mln € e un utile netto di 184,91 Mln €
(EUR) settembre 2026
YoY
Ricavi 99,79 Mln 343,70%
Utile lordo 99,79 Mln 343,70%
Utile netto 184,91 Mln 61,39%
EBITDA 184,93 Mln 61,39%

Dati fondamentali

Metrica Valore
Capitalizzazione di mercato
3,22 Mld €
Numero di azioni
55,15 Mln
Massimo/minimo a 52 settimane
61,70 € - 44,43 €
Rendimento da dividendo
4,20%
Dividendi TTM
2,46 €
Beta
0,93
Rapporto P/E
2,77
Rapporto PEG
0,01
Rapporto P/B
0,91
Rapporto P/S
13,57

Profilo aziendale

BB Biotech AG è un fondo azionario lanciato e gestito da Bellevue Asset Management AG. Il fondo investe nei mercati azionari pubblici di tutto il mondo. Investe principalmente in azioni di società impegnate nella produzione di farmaci e diagnostica basati sulla biotecnologia moderna. Il fondo utilizza un'analisi fondamentale per costruire il proprio portafoglio. BB Biotech AG è stata costituita il 9 novembre 1993 ed è domiciliata in Svizzera.

Nome
BB BIOTECH N
CEO
Daniel Koller
Sede centrale Kusnacht,
Svizzera
Sito web
Settore
Sanità
Industria
Biotecnologia
Quotazione in borsa
04/01/2000
Dipendenti 10

Simboli di borsa

Borsa Simbolo
XETRA
BBZA.DE
SIX
BION.SW
Hamburg
BBZA.HM
London
0JYO.L
München
BBZA.MU
🍪

Parqet  usa i cookie. Scopri di più